QLG2128
Phase 3Small molecule
Qilu Pharmaceutical Co., Ltd.QLG2128 is one of 30 small molecule programs targeting Osteoporosis. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
29
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
36 competitors in Osteoporosis
#DrugCompanyPhaseTrials
1Forteo
AAlmaject
Approved
Zometa
PfizerApproved
Fosamax
OOrganon and Co
Approved
Evista
Eli LillyApproved
Rocaltrol
Jazz PharmaceuticalsApproved
Estrace
Novo NordiskApproved
Sensipar
AmgenApproved
Calciferol
Jazz PharmaceuticalsApproved
Achromycin V
WWyeth-Lederle Vaccines
Approved
Jadelle
IItalian Network for Tumor Biotherapy Foundation
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for QLG2128. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details